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Abstract
Sodium nitroprusside (SNP), a widely used nitric oxide donor,
has recently been shown to mediate chondrocyte apoptosis by
generating reactive oxygen species, whereas more potent nitric
oxide donors do not induce chondrocyte apoptosis. The present
study was performed to investigate the protective effect of a low
concentration of SNP upon the cytotoxicity of chondrocytes to
higher concentrations of SNP, and to elucidate the underlying
mechanism. Human osteoarthritis chondrocytes were cultured
as monolayers, and first-passage cells were used for the
experiments. Chondrocyte death induced by 1 mM SNP was
completely inhibited by pretreating with 0.1 mM SNP. This
protective effect of SNP was replicated by the guanosine-3',5'κ-
cyclic monophosphate analog, DBcGMP. Protection from
chondrocyte death conferred by 0.1 mM SNP was mediated by
heme oxygenase 1 (HO-1), as was revealed by the increased
expression of HO-1 in 0.1 mM SNP pretreated chondrocytes
and by the reversal of this protective effect by the HO-1 inhibitor,
zinc protoporphyrin. SNP-mediated chondrocyte protection
correlated with the downregulation of both extracellular signal-
regulated protein kinase 1/2 and p38 kinase activation. SNP at
0.1 mM induced significant NF-κB activation as revealed by
electrophoretic mobility shift assays, and the inhibition of NF-κB
by MG132 or Bay 11-7082 nullified 0.1 mM SNP-mediated
chondrocyte protection. The upregulation of p53 and the
downregulation of Bcl-XL and Mcl-1 by 1 mM SNP were reversed
by 0.1 mM SNP pretreatment at the protein level by western
blotting. Our study shows that priming with 0.1 mM SNP
confers complete protection against cell death induced by 1 mM
SNP in human articular chondrocytes. This protective effect was
found to be correlated with the upregulation of both HO-1 and
NF-κB and with the concomitant downregulation of both
extracellular signal-regulated protein kinase 1/2 and p38
activation.
Introduction
Articular cartilage consists of chondrocytes, the only cell type
present, which are responsible for repairing tissue damage.
Chondrocyte death and the pertinent signaling pathway
involved have therefore been the focus of interest recently as
pathogenetic factors leading to joint cartilage degradation in
various forms of arthritides [1,2]. Several stimuli involved in the
pathophysiology of arthritis, including nitric oxide (NO), Fas
receptor ligation, and ceramide, have been reported to induce
chondrocyte death in vitro [3-5].
The pathogenetic involvement of NO in arthritis was first dem-
onstrated when levels of nitrite, a stable end product of NO
metabolism, were shown to be elevated in serum and synovial
fluid samples of rheumatoid arthritis patients and osteoarthritis
patients [6]. Moreover, because osteoarthritic cartilage pro-
duces large amounts of NO, it could serve as a powerful initi-
ator of chondrocyte death. In addition to the negative effects
of NO on cartilage matrix synthesis (i.e. the inhibition of carti-
lage matrix macromolecule neosynthesis), the enhancement of
matrix metalloproteinase activity, and the reduction of IL-1
CO = carbon monoxide; CoPP = cobalt protoporphyrin; DBcGMP = dibutylyl guanosine-3',5'-cyclic monophosphate; DMEM = Dulbecco's modified 
Eagle's medium; ERK = extracellular signal-regulated protein kinase; FCS = fetal calf serum; HO-1 = heme oxygenase 1; IL = interleukin; MAP = 
mitogen-activated protein; MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazdium bromide; NF = nuclear factor; NO = nitric oxide; NOC-5 = 1-
hydroxy-2-oxo-3-(3-aminopropyl)-3-isopropyl-1-triazene; SIN-1 = 3-morpholinosydnonimine; SNAP = S-nitroso-N-acetyl-L-penicillamine; SNP = 
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receptor antagonist synthesis, NO may be an important medi-
ator of cartilage degradation. However, the precise role of NO
in the induction of chondrocyte death is debatable. For exam-
ple, treatment with NO donors consistently induces cell death
in cultured chondrocytes [3,7], whereas the production of high
levels of endogenous NO by the overexpression of inducible
NO synthase in transfected chondrocytes was not found to
cause cell death [8]. This discrepancy may be attributed to the
use of chemical NO donors, which not only generate reactive
nitrogen species but also produce various secondary reac-
tions depending on the cellular milieu in vitro. A recent study
that employed diazeniumdiolates, which have been shown to
be reliable sources of NO, demonstrated that exogenous NO
is not cytotoxic to cultured chondrocytes per se, and that NO
can even be protective under certain conditions of oxidative
stress [9]. In addition, nitrite was found to exert a protective
effect upon hypochlorous acid-induced chondrocyte toxicity,
thus suggesting that NO has a novel cytoprotective role in
inflamed joints [10].
This paradoxical effect of NO on cytotoxicity indicates that pre-
vious results using sodium nitroprusside (SNP) or S-nitroso-N-
acetyl-L-penicillamine (SNAP) as NO donors should be cau-
tiously interpreted. It has recently been reported that a low
concentration of SNP exerts a protective effect against the
cytotoxicity induced by higher concentrations of SNP, or
against glucose deprivation in hepatocytes [11,12]. The
objective of this study was to investigate the influence of low
SNP concentrations upon the cytotoxicity induced by higher
concentrations of SNP in chondrocytes. We also explored the
mechanism of this low-concentration SNP-mediated
cytoprotection.
Materials and methods
Reagents
Nitrate/nitrite colorimetric assay kits were purchased from
Cayman Chemical (Ann Arbor, MI, USA). Ly83583 was pur-
chased from Calbiochem (San Diego, CA, USA), 1-hydroxy-2-
oxo-3-(3-aminopropyl)-3-isopropyl-1-triazene (NOC-5),
SNAP, SB202190, PD98059, MG132 and Bay 11-7082
were from Alexis (Carlsbad, CA, USA), and zinc protoporphy-
rin (ZnPP) and cobalt protoporphyrin (CoPP) were from Fron-
tier Scientific (Logan, UT, USA). Anti-phospho extracellular
signal-regulated protein kinase (ERK) 1/2, anti-phospho-p38,
anti-ERK 1/2, and anti-p38 were purchased from New Eng-
land Biolabs (Beverly, MA, USA), anti-Bcl-2 from Transduction
Laboratories (Lexington KY, USA), anti-Bax from Pharmingen
(San Diego, CA, USA), and anti-heme oxygenase 1 (anti-HO-
1), anti-Bcl-XL, anti-Mcl-1, anti-p53, anti-CIAP1 and anti-CIAP2
from Santa Cruz (Santa Cruz, CA, USA). All other reagents
were obtained from Sigma (St Louis, MO, USA) unless speci-
fied otherwise.
Chondrocyte culture
Cartilage samples were obtained from the femoral condyle
and from the tibial plateau of the knees of osteoarthritis
patients at the time of joint replacement surgery. All cartilage
samples were procured after obtaining oral informed consent
from the patients and institutional approval. Pieces of articular
cartilage were cut, minced, and incubated sequentially with
pronase and collagenase in DMEM until they had been
digested. Released cells were seeded at 4 × 106/plate in 10
cm culture plates in DMEM supplemented with 10% FCS, 1%
L-glutamine, and 1% Fungizone (Gibco, Grand Island, NY,
USA) and in DMEM supplemented with penicillin/streptomy-
cin (150 units/ml and 50 mg/ml, respectively). Confluent
chondrocytes were split once after about 7 days and were
seeded at high density, and these first-passage adherent
chondrocytes were then used in subsequent experiments.
Nitrate/nitrite quantification
NOC-5 was dissolved in 10 mM NaOH to produce a 200 mM
stock solution and was stored at -20°C. SNP, 3-morpholino-
sydnonimine (SIN-1), and SNAP were freshly dissolved in
water before each experiment. All NO donor compounds were
diluted with DMEM and added directly to cultured chondro-
cytes. The final products of NO in vivo are nitrite and nitrate,
the sum of which can be used as an index of total NO produc-
tion. Chondrocyte culture media were harvested after being
incubated for 24 hours with the respective NO donors, and
were then analyzed using a nitrate/nitrite colorimetric assay kit
as recommended by the manufacturer. Briefly, nitrate was con-
verted to nitrite using nitrate reductase, and then Griess rea-
gents were added to form a deep-purple azo compound.
Absorbance was measured at 540 nm using a plate reader to
determine the nitrite concentrations. The detection limit of the
assay was 1 µM.
Quantification and verification of cell death
Cell death was quantitated using the 3-(4,5-dimethylthiazol-2-
yl)-2,5 diphenyltetrazdium bromide (MTT) assay, as previously
described [13]. Briefly, chondrocytes were seeded at 4 × 104/
100  µl/well in 96-well microtiter plates. Cell death was
induced by treating with 1 mM SNP. To protect cells, chondro-
cytes were treated with 0.1 mM SNP, 50 µM CoPP, or 1 mM
dibutylyl guanosine-3',5'-cyclic monophosphate (DBcGMP)
14 hours prior to being treated with 1 mM SNP. MTT was then
added to each well to a final concentration of 0.125 mg/ml
after they had been incubated with 1 mM SNP for 24 hours,
and plates were incubated at 37°C for a further 3 hours. The
formazan product obtained was solubilized with 100 µl
dimethylsulfoxide and optical densities were read at 595 nm.
Percentage cell survival was calculated by taking the optical
density of cells post-treatment, dividing this by the optical den-
sity of the untreated control cells, and multiplying by 100. Cell
death was also verified by flow cytometry. Chondrocytes were
trypsinized after treatment and were sedimented, and the cell
pellets obtained were washed and stained with 100 µg/mlAvailable online http://arthritis-research.com/content/7/3/R526
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propidium iodide solution for 15 min. For each sample, 104
cells were analyzed by FACS II flow cytometry (Becton Dick-
inson, Mountain View, CA, USA).
Western blot
Cellular proteins were extracted in lysis buffer containing 50
mM sodium acetate, pH 5.8, 10% v/v SDS, 1 mM ethylene
diaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride,
and 1 µg/ml aprotinin at 4°C. Samples were electrophoresed
on 12% SDS-polyacrylamide gel, and transferred to polyvinyli-
dene difluoride membranes. Blots were blocked with Tris-buff-
ered saline containing 5% non-fat milk at room temperature for
1 hour, and then incubated with the respective antibodies
overnight at 4°C. Finally, blots were incubated with 1:5000
peroxidase-conjugated goat anti-mouse or anti-rabbit IgG
(Biorad, Hercules, CA, USA) for 1 hour. Bound immunoglobu-
lin was detected by enhanced chemiluminescence (Amer-
sham, Bucks, UK).
Electrophoretic mobility shift assay
Nuclear extracts from chondrocytes were prepared from 2 ×
106 cells, as described previously with minor modification
[14]. Briefly, cells were incubated on ice for 15 min with
homogenization buffer containing 10 mM HEPES-KOH, 4 mM
MgCl2, 10 mM KCl, 1 mM NaF, 0.5 mM dithiothreitol, 1 mM
phenylmethylsulfonyl fluoride, and 20 µg/ml leupeptin. After
adding detergent, the lysates were centrifuged at 3000g for 5
min. Pellets were resuspended in extraction buffer containing
20 mM HEPES-KOH, 1.5 mM MgCl2, 420 mM NaCl, 25%
glycerol, 1 mM NaF, 0.5 mM dithiothreitol, 1 mM phenylmeth-
ylsulfonyl fluoride, 20 µg/ml leupeptin, and 0.2 mM ethylene
diaminetetraacetic acid. After incubation on ice and centrifu-
gation, supernatants were collected, the protein content was
measured, and 5 µg portions of extracts were used for the
binding reaction. A consensus double-stranded NF-κB probe
was obtained from Promega (Madison, WI, USA), and was
end-labeled using γ-32P-adenosine-5-triphosphate. After incu-
bating nuclear extracts in 2 µl gel binding buffer (Promega),
end-labeled probe was added (100,000 cpm/sample). Sam-
ples were then incubated for 20 min and were loaded onto 4%
nondenaturing polyacrylamide gels. Electrophoresis was run
for 3 hours at 4°C. Protein complexes were identified by
autoradiography.
Data analysis
Data are expressed as means ± standard deviations. The
paired t test was used to compare controls and treatment con-
ditions, and significance was accepted at a confidence level of
95% (P < 0.05).
Results
Chondrocyte death does not correlate with the amount 
of NO released by NO donors
A nitrate/nitrite assay kit was used to determine the amount of
NO generated by the various NO donor compounds, SNP,
NOC-5, SIN-1, and SNAP [15]. As was reported previously
[9], the different NO donors released variable degrees of NO
in the culture medium; SNP was the least efficient NO pro-
ducer (Fig. 1a). A one millimolar concentration of SNP yielded
about 12% of the NO produced by 1 mM diazeniumdiolate,
NOC-5. However, 1 mM SNP led to almost complete
chondrocyte death, whereas the same concentration of NOC-
5 caused no appreciable cell death 24 hours after treatment
(Fig. 1b). Other NO donors, SIN-1 and SNAP, also induced
significant chondrocyte death at 2 mM concentrations. The
amounts of NO produced by 2 mM SIN-1 or 2 mM SNAP were
10-fold and 8.9-fold higher than that produced by 2 mM SNP,
respectively, but the levels of cell death induced were not as
profound as that produced by 2 mM SNP. These results dem-
onstrate that the amount of NO produced by a NO donor is not
correlated with chondrocyte death.
0.1 mM SNP protects chondrocytes from death induced 
by 1 mM SNP
It was previously reported that pretreatment of hepatocytes
with a low dose of SNP significantly inhibited high-dose SNP-
induced hepatocyte death [11,12]. In order to determine
whether this phenomenon also occurs in chondrocytes, we
treated chondrocytes with a low, noncytotoxic concentration
of SNP (i.e. 0.1 mM). As shown in Fig. 2a, priming the
chondrocytes with 0.1 mM SNP for 14 hours completely inhib-
ited the cell death induced by 1 mM SNP. However, pretreat-
ment with concentrations higher than 0.2 mM SNP did not
confer protection (data not shown). Pretreatment with 0.1 mM
SNP for 1–6 hours was also protective (data not shown), but
because the degree of protection was greatest for the 14-hour
pretreatment, chondrocytes were pretreated with 0.1 mM
SNP for 14 hours in all subsequent experiments.
Inhibition of cell death was also verified by fluorescence-acti-
vated cell sorting analysis of treated chondrocytes stained
with propidium iodide (Fig. 2b). Because low concentrations
of SNP are known to protect a murine macrophage cell line via
the cGMP signaling pathway [16], we investigated whether
cGMP is also protective in chondrocytes. Chondrocytes were
thus pretreated with 1 mM DBcGMP, a cell-permeable cGMP
analog, for 14 hours before administering 1 mM SNP. As is
shown in Fig. 2a, pretreatment with DBcGMP led to the com-
plete inhibition of 1 mM SNP-mediated chondrocyte death. In
addition, pretreatment with LY83583, a soluble guanylate
cyclase inhibitor, negated the protective effect of 0.1 mM SNP
pretreatment, thus implicating the cGMP pathway in 0.1 mM
SNP-mediated chondrocyte cytoprotection.
NOC-5 protects chondrocytes from 1 mM SNP-induced 
death
We also investigated whether 0.1 mM SNP-mediated cytopro-
tection is replicated by other NO donors. Low concentrations
(0.1–0.5 mM) of SIN-1 or SNAP did not protect from the cell
death induced by 1 mM SNP, but rather acted synergisticallyArthritis Research & Therapy    Vol 7 No 3    Kim et al.
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with SNP to enhance the cytotoxicity of subsequent 1 mM
SNP treatment (data not shown). On the other hand, NOC-5
slightly inhibited 1 mM SNP-induced chondrocyte death, with
maximal effect at 0.3 mM (Fig. 3).
The protection conferred by low concentration SNP is 
mediated by HO-1 upregulation
Because 0.1 mM SNP inhibited chondrocyte cytotoxicity
induced by 1 mM SNP more so than the other NO donors
examined, we investigated the mechanism of 0.1 mM SNP-
mediated protection. Heme oxygenase is a rate-limiting
enzyme in heme catabolism, and leads to the generation of
bilirubin, free iron, and carbon monoxide (CO) [17-19]. HO-1
is inhibited by various metalloprotoporphyrins (e.g. ZnPP and
tin protoporphyrin). Previous reports reveal that HO-1 overex-
pression is cytoprotective in multiple models including endo-
toxemia, shock, and ischemia/reperfusion [20-22].
Pretreatment of chondrocytes with the HO-1 inducer CoPP at
50 µM reproduced the cytoprotective effect of 0.1 mM SNP
upon 1 mM SNP-induced cell death (Fig. 4a). Conversely, the
co-treatment of chondrocytes with the HO-1 inhibitor ZnPP
and 0.1 mM SNP attenuated the cytoprotective effect of 0.1
mM SNP. HO-1 was time-dependently induced by 0.1 mM
SNP in chondrocytes, and western blot revealed that HO-1 is
significantly upregulated after pretreatment with 0.1 mM SNP
for 14 hours (Fig. 4b,c). CoPP at 50 µM upregulated HO-1 as
was expected, and DBcGMP was also found to upregulate
HO-1 in chondrocytes (Fig. 4c).
The protection conferred by 0.1 mM SNP is correlated 
with the downregulation of ERK 1/2 and p38 kinase 
activation
SNP at 1 mM caused the upregulation of both ERK 1/2 and
p38 phosphorylation followed by chondrocyte death (Fig. 5a),
and priming with 0.1 mM SNP reversed this pattern of
mitogen-activated protein (MAP) kinase activation, by
Figure 1
Quantification of nitrate/nitrite levels and the cell death induced by different nitric oxide (NO) donor compounds Quantification of nitrate/nitrite levels and the cell death induced by different nitric oxide (NO) donor compounds. Chondrocytes were obtained from 
the femoral condyle and the tibial plateau of knee osteoarthritis patients, cultured in monolayers, and seeded at 4 × 104/100 µl/well in 96-well micro-
titer plates. First-passage chondrocytes were used in the subsequent experiments. Chondrocytes were treated with the respective NO donor com-
pounds for 24 hours. (a) Chondrocyte culture media were harvested and analyzed with a nitrate/nitrite colorimetric assay kit, as described in 
Materials and methods. (b) Cell death was quantitated using the 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazdium bromide (MTT) assay. MTT was 
added to each well after the collecting medium. Percentage cell survival was calculated by dividing the optical density of treated cells by the optical 
density of untreated control cells, and multiplying by 100. Cell survival in control culture was set at 100%. * P < 0.05 versus control. Data shown are 
the means and standard deviations of duplicate experiments on three different donors. NOC-5, 1-hydroxy-2-oxo-3-(3-aminopropyl)-3-isopropyl-1-tri-
azene; SIN-1, 3-morpholinosydnonimine; SNAP, S-nitroso-N-acetyl-L-penicillamine.Available online http://arthritis-research.com/content/7/3/R526
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downregulating both ERK 1/2 and p38 phosphorylation. Pre-
treatment with the ERK 1/2 inhibitor PD98059 partially pro-
tected chondrocytes from death mediated by 1 mM SNP. The
P38 kinase inhibitor SB202190 protected 1 mM SNP-medi-
ated chondrocyte death only at 10 µM, which may inhibit path-
ways other than p38 (Fig. 5b). This result shows that the
protection conferred by 0.1 mM SNP correlates with the
downregulation of both ERK 1/2 and p38 kinase activation,
but only the activation of ERK 1/2 was found to be directly
responsible for chondrocyte death induced by 1 mM SNP.
The protection conferred by 0.1 mM SNP is negated by 
NF-κB suppression
Because NF-κB activation plays a pivotal role in protecting
chondrocytes from apoptosis induced by death signals
[23,24], the role of NF-κB activation in the protective effect of
0.1 mM SNP was examined. Activation of NF-κB by 0.1 mM
SNP pretreatment was verified by electrophoretic mobility shift
assay (Fig. 6a). Co-treatment with the NF-κB inhibitor Bay 11-
7082 and with 0.1 mM SNP completely negated the protec-
tive effect of 0.1 mM SNP (Fig. 6a). Because Bay 11-7082
was found to be cytotoxic to chondrocytes (data not shown),
another NF-κB inhibitor MG132, which is not cytotoxic to
chondrocytes, was also tested. It was found that MG132 co-
treatment also negated the protection conferred by 0.1 mM
SNP. This result implies that NF-κB activation participates in
the chondrocyte protection mediated by 0.1 mM SNP.
Figure 2
Protective effect of low-concentration sodium nitroprusside (SNP) on human articular chondrocytes Protective effect of low-concentration sodium nitroprusside (SNP) on human articular chondrocytes. Cell death was induced by treating chondro-
cytes with 1 mM SNP for 24 hours. To protect them from cell death, chondrocytes were treated with 0.1 mM SNP or 1 mM dibutylyl guanosine-3',5'-
cyclic monophosphate (DBcGMP) 14 hours prior to 1 mM SNP treatment. To inhibit cyclic guanylase, 1 µM Ly83583 was added with 0.1 mM of 
SNP. (a) Cell death was quantitated using the 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazdium bromide assay. Cell survival in control cultures was 
set at 100%. Data shown are the means and standard deviations of triplicate experiments from at least three different donors. * P < 0.05 versus con-
trol. (b) Cell death was verified by propidium iodide staining and fluorescence-activated cell sorting analysis. Chondrocytes were trypsinized after 
treatment and were sedimented. Cell pellets obtained were washed and stained in 100 µg/ml propidium iodide solution for 15 min. For each sample, 
104 cells were analyzed. Data are representative of samples from four different donors. Percentage values denote propidium iodide positive (dead) 
chondrocytes.
Figure 3
Effect of 1-hydroxy-2-oxo-3-(3-aminopropyl)-3-isopropyl-1-triazene  (NOC-5) on the cytotoxic effect of 1 mM sodium nitroprusside (SNP) in  human articular chondrocytes Effect of 1-hydroxy-2-oxo-3-(3-aminopropyl)-3-isopropyl-1-triazene 
(NOC-5) on the cytotoxic effect of 1 mM sodium nitroprusside (SNP) in 
human articular chondrocytes. Cell death was induced by treating 
chondrocytes with 1 mM SNP for 24 hours. To protect them from cell 
death, chondrocytes were treated with various concentrations of NOC-
5 for 14 hours prior to 1 mM SNP treatment. Cell death was quanti-
tated by the 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazdium bromide 
assay. Cell survival in control cultures was set at 100%. Data are the 
means and standard deviations of triplicate experiments on nine differ-
ent donors. * P < 0.05 versus treatment with 1 mM SNP without NOC-
5 pretreatment.Arthritis Research & Therapy    Vol 7 No 3    Kim et al.
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The protection conferred by 0.1 mM SNP correlates with 
the upregulation of Bcl-2 family proteins and the 
downregulation of p53
The Bcl-2 family proteins MCl-1 and Bcl-XL were both down-
regulated during the cell death induced by 1 mM SNP (Fig. 7).
This downregulation was reversed by priming chondrocytes
with 0.1 mM SNP. On the contrary, p53 was upregulated dur-
ing 1 mM SNP-mediated chondrocyte death, but was down-
regulated by 0.1 mM SNP pretreatment (Fig. 7). The
expressions of other Bcl-2 family members, such as Bcl-2 and
Bax, or of the IAP family, c-IAP1, c-IAP2, or XIAP, were unaf-
fected (data not shown).
Discussion
The mechanism of SNP-mediated chondrocyte death has
been extensively investigated, and has usually been viewed as
a NO-mediated form of chondrocyte apoptosis. In line with a
previous result [9], our result shows that SNP is the least
potent in terms of producing exogenous NO in chondrocyte
culture, yet it is the most potent inducer of chondrocyte death.
We cannot rule out the role played by NO in SNP-mediated
chondrocyte death, because it is not possible to quench the
NO produced by SNP treatment selectively. However, it is
believed unlikely that NO is the sole mediator of SNP-induced
chondrocyte death and peroxynitrite, a reaction product of NO
and superoxide anions, or the primary byproducts of the
decomposition of SNP, such as the cyanide anion or pentacy-
anoferrate complex, might contribute to its cytotoxicity
[25,26].
Cytotoxic concentrations of SNP are associated with a 20-fold
increase in NO production versus noncytotoxic concentra-
tions, which contrasts with the actions of other nontoxic NO
donors, which increase NO concentrations several hundred
fold. It was of interest to find that pretreatment with 0.1 mM
SNP led to complete chondrocyte protection against the toxic
effect of 1 mM SNP. NOC-5, a diazeniumdiolate, also inhibited
1 mM SNP-induced chondrocyte death. However, despite the
much higher level of NO formed by NOC-5, the degree of pro-
tection it conferred was smaller than that conferred by 0.1 mM
SNP. It is thus also likely that the protection conferred by low-
concentration SNP is not solely explained by NO production.
It remains for further research to identify the other cytoprotec-
tive component mediated by low-concentration SNP.
In the present study, we used chondrocytes obtained from
osteoarthritis patents at the advanced stage, because it was
not possible to obtain sufficient chondrocytes from normal car-
tilage to carry out the in vitro experimentation. Although it is
not possible to extrapolate our results to normal chondrocytes,
a limited experiment utilizing normal cartilage obtained from a
femoral head revealed that 0.1 mM SNP protected
Figure 4
Protective effect of heme oxygenase 1 (HO-1) on human chondrocytes Protective effect of heme oxygenase 1 (HO-1) on human chondrocytes. (a) Cell death was induced by treating chondrocytes with 1 mM sodium 
nitroprusside (SNP) for 24 hours. For HO-1 induction, chondrocytes were treated with 50 µM cobalt protoporphyrin (CoPP) 14 hours prior to treat-
ing them with 1 mM SNP. For HO-1 inhibition, chondrocytes were treated with 1 µM zinc protoporphyrin (ZnPP) along with 0.1 mM SNP. Cell death 
was quantitated using the 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazdium bromide assay. Cell survival in control culture was set at 100%. Data 
shown are the means and standard deviations of triplicate experiments from at least four different donors. * P < 0.05 versus control. (b) Induction of 
HO-1 by 0.1 mM SNP treatment in human chondrocytes was analyzed by western blotting. Protein was extracted from chondrocytes after the indi-
cated incubation periods and 20 µg each protein sample was separated by 12% SDS-PAGE and blotted with anti-HO-1 antibody. Data are repre-
sentative of two samples from different donors. (c) Upregulation of HO-1 by pretreating chondrocytes with 0.1 mM SNP, 50 µM CoPP, or 1 mM 
dibutylyl guanosine-3',5'-cyclic monophosphate (DBcGMP). Chondrocytes were treated or not treated with the indicated chemicals for 14 hours 
and were then treated with 1 mM SNP for 2 hours. Protein was extracted from chondrocytes and 20 µg each protein sample was separated by 12% 
SDS-PAGE and blotted with anti-HO-1 antibody. The data shown are representative of five samples from different donors.Available online http://arthritis-research.com/content/7/3/R526
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chondrocytes from cell death induced by 1 mM SNP to the
same degree as was observed in osteoarthritis chondrocytes
(data not shown).
To elucidate the signaling mechanism involved in low-concen-
tration SNP-mediated cytoprotection, cGMP dependence
was first examined. In the present study, the soluble guanylate
cyclase inhibitor LY83583 was found to inhibit the cytoprotec-
tive effect of 0.1 mM SNP, whereas DBcGMP, a cell-permea-
ble cGMP analog, attenuated the cell death induced by 1 mM
SNP, indicating a cGMP-mediated cytoprotective mechanism.
A previous study showed that the protection afforded by
DBcGMP against SNP-induced death in RAW264 cells is
mediated by protein kinase G activation, which results in the
inhibition of cytochrome c release [16]. Because the inhibition
of cytoprotection by Ly83583 was incomplete in the present
study, and because other NO donors such as SIN-1 and
SNAP, which also induce cGMP, failed to protect chondro-
cytes, other cytoprotective pathways were also examined.
Recent evidence has demonstrated the critical importance of
HO-1 expression in the mediation of antioxidant, anti-inflam-
matory, and anti-apoptotic effects [19,27,28]. HO-1 is distrib-
uted ubiquitously and is induced strongly by a variety of
physiologic and pathophysiologic stimuli, including heme,
heavy metals, inflammatory cytokines, endotoxins, and NO
[12]. The pretreatment of chondrocytes with the HO-1 inducer
CoPP reproduced the cytoprotective effect of 0.1 mM SNP
against 1 mM SNP-induced cell death, whereas the co-treat-
ment of chondrocytes with the HO-1 inhibitor ZnPP and 0.1
mM SNP inhibited this cytoprotective effect. Moreover, HO-1
was found to be induced by 0.1 mM SNP treatment in
chondrocytes.
The mechanism by which HO-1 protects from cell death has
been postulated to involve several mechanisms, although the
role of CO produced by the HO-1 degradation of heme has
received most attention. Pharmacologic CO donors have also
been demonstrated to protect hepatocytes from the death
induced by glucose deprivation or anti-Fas [29]. Zuckerbraun
and colleagues [30] recently showed that CO mediates hepa-
tocyte protection by activating NF-κB, which in the presence
of an inflammatory stimulus upregulates inducible NO syn-
thase and leads to NO production. This mechanism implies a
synergy between CO and NO in the provision of cytoprotec-
tion. Increased HO-1 activity also results in the generation of
bilirubin, an antioxidant capable of scavenging peroxy radicals
and inhibiting lipid peroxidation [29]. Finally, ferritin is another
catalytic byproduct of HO-1 induction, and sequesters the free
iron produced during heme catalysis, which reduces intracel-
lular free iron and thus has an anti-oxidant effect [31]. The
downstream process of cytoprotection conferred by the
Figure 5
The regulation of extracellular signal-regulated protein kinase (ERK) 1/2 and p38 phosphorylation on 0.1 mM sodium nitroprusside (SNP) pretreated  chondrocytes The regulation of extracellular signal-regulated protein kinase (ERK) 1/2 and p38 phosphorylation on 0.1 mM sodium nitroprusside (SNP) pretreated 
chondrocytes. (a) Chondrocytes were treated with 0.1 mM SNP 14 hours prior to treatment with 1 mM SNP and the phosphorylations of ERK 1/2 
and p38 were analyzed after 4 hours by western blotting. Protein was extracted from chondrocytes and 20 µg each protein sample was separated 
by 12% SDS-PAGE and blotted with anti-phospho-ERK 1/2 or anti-phospho-p38. The expressions of ERK 1/2 and p38 were also determined by 
western blot analysis. Data are representative of samples from four different donors. (b) Effect of ERK 1/2 and p38 kinase inhibition on the chondro-
cyte death induced by 1 mM SNP. Cell death was induced by treating chondrocytes with 1 mM SNP for 24 hours. To inhibit ERK 1/2 or p38 kinase, 
chondrocytes were pretreated with 10, 20, or 50 µM PD98059 or with 1, 5, or 10 µM SB202190, respectively, for 2 hours before treating them with 
1 mM SNP. Cell death was quantitated by the 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazdium bromide assay. Cell survival in control culture was 
set at 100%. Data are the means and standard deviations of duplicate experiments from at least three different donors. * P < 0.05 versus treatment 
with 1 mM SNP without pretreatment.Arthritis Research & Therapy    Vol 7 No 3    Kim et al.
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upregulation of HO-1 in human chondrocytes warrants further
study. HO-1 was recently detected in human cartilage and in
chondrocytes, and was found to be downregulated by proin-
flammatory cytokines and to be upregulated by anti-inflamma-
tory cytokine, suggesting that HO-1 is a component of the
protective mechanisms in human cartilage [32].
In a previous report, cell death and the dedifferentiation of
chondrocytes was demonstrated to be regulated oppositely
by two MAP kinase subtypes, ERK 1/2 and p38 kinase [33].
In rabbit chondrocytes, SNP increased both p38 kinase and
ERK activation, and SNP-induced p38 kinase functioned as an
induction signal for apoptosis and in the maintenance of the
chondrocyte phenotype, whereas ERK activity caused dedif-
ferentiation and operated as a prosurvival signal. Although our
results show that high-dose SNP induces both p38 and ERK
phosphorylation in line with the previous report [33], the down-
regulation of ERK 1/2 phosphorylation by low-concentration
SNP was associated with chondrocyte protection rather than
cell death in our human chondrocyte cultures.
The role played by ERK inhibition in chondrocyte death is not
without controversy. Whereas one report showed that the
blocking of MAP kinase kinase upstream of ERK by U0126
induces chondrocyte death, another report showed that ERK
1/2 or p38 kinase inhibition prevents SNP-induced chondro-
cyte death [34,35]. We found that the inhibition of ERK 1/2
leads to partial protection against 1 mM SNP-mediated
chondrocyte death, but SB202190 at low concentrations,
which specifically suppresses p38 activation, did not sup-
press it. This discrepancy probably stems from the differences
in culture conditions, and concentrations of the inhibitors
used. According to our result, although the protection con-
ferred by 0.1 mM SNP correlates with the downregulation of
both ERK 1/2 and p38 kinase activation, only the activation of
ERK 1/2 is directly responsible for chondrocyte death induced
by 1 mM SNP.
Finally, the role played by NF-κB activation in 0.1 mM SNP-
mediated chondrocyte protection was investigated because
NF-κB has been reported to serve as a survival signal in both
tumor necrosis factor alpha and anti-Fas-mediated chondro-
cyte death [23,24]. NF-κB activation was observed after pre-
treating 0.1 mM SNP in human chondrocytes. Pretreating with
the NF-κB inhibitors MG132 or Bay 11-7085 completely abol-
ished the protection conferred by 0.1 mM SNP. Because this
inhibition of the protective effect of SNP was greater than that
conferred by either HO-1 or cyclic guanylase inhibitor, we
Figure 6
NF-κB activation was correlated with chondrocyte survival mediated by low-concentration sodium nitroprusside (SNP) NF-κB activation was correlated with chondrocyte survival mediated by low-concentration sodium nitroprusside (SNP). (a) Activation of NF-κB in 
0.1 mM SNP-treated chondrocytes. Chondrocytes were treated with 0.1 mM SNP for 14 hours with or without NF-κB inhibitors and the activation of 
NF-κB was analyzed by electrophoretic mobility shift assay. Nuclear extracts were prepared from 2 × 106 cells, and 5 µg portions of extracts were 
used for the binding reaction. Nuclear extracts were incubated in gel binding buffer with radiolabeled consensus double-stranded NF-κB probe, and 
samples were loaded onto 4% nondenaturing polyacrylamide gel. Protein complexes were identified by autoradiography. Data are representative of 
three samples from different donors. (b) Effect of the inhibition of NF-κB activation on the protective effect of 0.1 mM SNP on human chondrocytes. 
Cell death was induced by treating chondrocytes with 1 mM SNP for 24 hours. To inhibit NF-κB, chondrocytes were co-treated with 20 µM Bay 11-
7082 or MG132 and 0.1 mM SNP for 14 hours before treating with 1 mM SNP. Cell death was quantitated by the 3-(4,5-dimethylthiazol-2-yl)-2,5 
diphenyltetrazdium bromide assay. Cell survival in the control culture was set at 100%. Data are the means and standard deviations of triplicate 
experiments from at least three different donors. * P < 0.05 versus control.Available online http://arthritis-research.com/content/7/3/R526
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believe that NF-κB has a pivotal role in the protective mecha-
nism signaled by low-dose SNP in chondrocytes.
Of the regulators of cell survival, the expressions of p53, Bcl-
XL, and Mcl-1 were significantly affected by 0.1 mM SNP pre-
treatment. The upregulation of p53 induced by 1 mM SNP was
downregulated by 0.1 mM SNP pretreatment. Although we did
not determine the mechanistic role of p53 phosphorylation, it
is generally recognized that the phosphorylation of p53 leads
to its accumulation, and that p53 is phosphorylated either indi-
rectly or directly by c-Jun N terminal kinase, by p38 kinase, or
by ERK [36-38]. We hypothesize that 1 mM SNP induced p38
kinase and ERK activity in chondrocytes and phosphorylated
p53, resulting in p53 accumulation, and that this was negated
by 0.1 mM SNP pretreatment via the downmodulation of these
MAP kinases. Of the Bcl-2 family members, the
downregulations of Bcl-XL and Mcl-1, both anti-apoptotic spe-
cies, by 1 mM SNP was reversed by 0.1 mM SNP.
Despite the marked improvements made in our understanding
of the mechanisms of chondrocyte apoptosis over the past
several years, it is unclear whether chondrocyte apoptosis is
the major mechanism of cartilage degradation or merely a
byproduct of tissue degeneration. Thus, whether the modula-
tion of apoptosis represents a feasible therapeutic target for
the treatment of osteoarthritis is not obvious at the moment. A
recent report showing that the intra-articular instillation of the
pan-caspase inhibitor zVAD-fmk into the knees of rabbits
induced to osteochondral injury led to a significant reduction
in chondrocyte apoptosis implies that apoptosis inhibitors
could be used to inhibit chondrocyte death in traumatic carti-
lage injury [39].
Conclusion
The present study shows that the widely used NO donor SNP
at 1 mM concentration mediates chondrocyte death strongly
despite its relatively poor ability to produce NO compared with
other NO donors. Pretreating chondrocytes with SNP at 0.1
mM (a noncytotoxic concentration) protects the cells against
1 mM SNP cytotoxicity. This protective pathway was found to
be related to four factors: cyclic GMP, HO-1, MAP kinase, and
NF-κB. The study elucidates the survival pathway inherent in
chondrocytes, and provides strategic information for the
development of new therapeutics based on the regulation of
chondrocyte death
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